Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure Protects against Highly Pathogenic Simian/Human Immunodeficiency Virus Infection in Macaques
スポンサーリンク
概要
- 論文の詳細を見る
In the absence of any effective vaccine against human immunodeficiency virus (HIV), current anti-retroviral drugs may be suitable for pre-exposure prophylaxis (PrEP). Previous large clinical trials showed that PrEP reduced HIV infection in high-risk populations. Emtricitabine/tenofovir (FTC/TDF) may be a suitable agent for PrEP. FTC/TDF PrEP efficacy was evaluated using a highly pathogenic simian/human immunodeficiency virus (SHIV) in a non-human primate model of AIDS, the SHIV-KS661c/cynomolgus monkey model. Double oral administration of FTC/TDF (20/30 mg/kg), at 24 h and a few minutes prior to exposure, completely protected 2/3 monkeys from infection. Interestingly, a single oral administration 2 weeks before viral exposure moderately rescued CD4 cells, although the data did not reach statistical significance. These results are consistent with previous primate studies and with recent clinical data.
著者
-
Nakasone Tadashi
Aids Research Center National Institute Of Infectious Disease
-
YAMAMOTO Naoki
AIDS Research Center, National Institute of Infectious Diseases
-
Yamamoto Naoki
Aids Research Center National Institute Of Infectious Diseases
-
Murakami Tsutomu
Aids Research Center National Institute Of Infectious Diseases
-
Nakasone Tadashi
AIDS Research Center, National Institute of Infectious Diseases
関連論文
- Synthesis of a CC Chemokine, vMIP-II, Encoded by Kaposi's Sarcoma-Associated Herpesvirus and Its Biological Activity
- Development of the Chemokine Receptor CXCR4 Antagonists as Multi-Pharmaceutical Agents Involving a New Class of Low Molecular Weight Antagonists
- Synthesis and Biological Evaluation of Peptidomimetic Analogs of the CXCR4 Antagonist FC131
- The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases Including AIDS, Cancer and Rheumatoid Arthritis
- New Leads of Low Molecular Weight CXCR4 Antagonists Based on Enhancement of the T140-based Pharmacophores
- CXCR4 Antagonists Identified as Anti-Cancer-Metastatic Agents
- HIV-cell Fusion Inhibitors Targeted to the HIV Second Receptor : T22 and Its Downsized Analogs with High Activity
- Design, Synthesis and Activity of Shortened Analogs of an Anti-HIV Peptide, T22
- Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells
- Synthesis of Sulfated Deoxy-Ribofuranans Having Selective Anti-AIDS Virus Activity by Ring-Opening Copolymerization of 1,4-Anhydro Ribose Derivatives
- Molecular Size of an Anti-HIV Peptide, T22, Can Be Reduced without Loss of the Activity
- STRUCTURE-ACTIVITY RELATIONSHIPS OF TACHYPLESIN ANALOGS AS ANTI-HIV AGENT
- STRUCTURES AND ACTIVITIES OF TANNINS IN CRUDE DRUGS (4) : EFFECTS ON PHAGOCYTES AND VIRUSES
- Identification of Sequential Motifs Relevant to Inhibitory Activity against HIV Integrase
- Detection of HIV-Gag p24-Specific Antibodies in Sera and Saliva of HIV-1-Infected Aduits and in Sera of Infants Born to HIV-1-Infected Mothers
- Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists
- Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis
- Separate elements are required for ligand-dependent and -independent internalization of metastatic potentiator CXCR4
- Efficient Synthesis of Cyclic RGD Pseudopeptide with (E)-Alkene Dipeptide Isostere and Its Biological Activity
- Identification of a Polyphemusin Analog(T22)-Zn(II) Complex by Mass Spectrometric Analysis and Its Anti-HIV Activity
- Identification of Binding Proteins of an Anti-HIV Peptide, T22
- Recombinant Vaccinia DIs Expressing Simian Immunodeficiency Virus Gag and Pol in Mammalian Cells Induces Efficient Cellular Immunity as a Safe Immunodeficiency Virus Vaccine Candidate
- The Normalization of Guinea Pig Leukocyte Fractions and Lymphocyte Subsets in Blood and Lymphoid Tissues using a Flow Cytometric Procedure
- Solution RNA Structures of the HIV-1 Dimerization Initiation Site in the Kissing-Loop and Extended-Duplex Dimers
- Development of Inhibitory Peptides against HIV-1 Integrase
- Structure-Activity Relationship Study of CXCR4 Antagonists on the Cyclic Pentapeptide Scaffold : Identification of New Pharmacophore Moieties
- Development of Fluorescent Labeled CXCR4 Specific Ligand for Imaging and Fluorescence-Based Screening
- Synthesis and Evaluation of CXCR4-derived Peptides Targeting the Development of AIDS Vaccines
- Structural Modulation Study of Inhibitory Compounds for Ribonuclease H Activity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase
- Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure Protects against Highly Pathogenic Simian/Human Immunodeficiency Virus Infection in Macaques